© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Dyadic International, Inc. (DYAI) stock surged +2.54%, trading at $0.77 on NASDAQ, up from the previous close of $0.75. The stock opened at $0.76, fluctuating between $0.76 and $0.78 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| May 05, 2026 | 0.76 | 0.78 | 0.76 | 0.77 | 20.85K |
| May 04, 2026 | 0.77 | 0.78 | 0.72 | 0.75 | 22K |
| Apr 30, 2026 | 0.75 | 0.79 | 0.74 | 0.78 | 4.09K |
| Apr 29, 2026 | 0.85 | 0.85 | 0.70 | 0.76 | 364.87K |
| Apr 28, 2026 | 0.85 | 0.85 | 0.80 | 0.81 | 27.68K |
| Apr 27, 2026 | 0.84 | 0.85 | 0.82 | 0.82 | 33.83K |
| Apr 23, 2026 | 0.93 | 0.93 | 0.84 | 0.87 | 34.86K |
| Apr 22, 2026 | 0.82 | 0.85 | 0.82 | 0.83 | 102.16K |
| Apr 21, 2026 | 0.88 | 0.88 | 0.81 | 0.84 | 87.38K |
| Apr 20, 2026 | 0.88 | 0.88 | 0.87 | 0.88 | 8.08K |
| Apr 17, 2026 | 0.88 | 0.88 | 0.88 | 0.88 | 56.47K |
| Apr 16, 2026 | 0.88 | 0.89 | 0.87 | 0.88 | 51.56K |
| Apr 14, 2026 | 0.85 | 0.88 | 0.85 | 0.87 | 58.61K |
| Apr 13, 2026 | 0.90 | 0.94 | 0.86 | 0.86 | 22.54K |
| Apr 10, 2026 | 0.91 | 0.91 | 0.80 | 0.89 | 35.49K |
| Apr 09, 2026 | 0.88 | 0.93 | 0.88 | 0.88 | 7.36K |
| Apr 08, 2026 | 0.95 | 0.95 | 0.87 | 0.89 | 12.11K |
| Apr 07, 2026 | 0.87 | 0.91 | 0.87 | 0.88 | 6.78K |
| Apr 06, 2026 | 0.88 | 0.92 | 0.86 | 0.87 | 36.3K |
| Apr 02, 2026 | 0.86 | 0.91 | 0.81 | 0.89 | 33.3K |
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
| Employees | 6 |
| Beta | 1.21 |
| Sales or Revenue | $2.90M |
| 5Y Sales Change% | 1.15% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |